Suppr超能文献

支架变形鉴定出3-吡啶基氮杂环丁烷脲是烟酰胺磷酸核糖基转移酶(NAMPT)的抑制剂。

Scaffold Morphing Identifies 3-Pyridyl Azetidine Ureas as Inhibitors of Nicotinamide Phosphoribosyltransferase (NAMPT).

作者信息

Palacios Daniel S, Meredith Erik L, Kawanami Toshio, Adams Christopher M, Chen Xin, Darsigny Veronique, Palermo Mark, Baird Daniel, George Elizabeth L, Guy Chantale, Hewett Jeffrey, Tierney Laryssa, Thigale Sachin, Wang Louis, Weihofen Wilhelm A

机构信息

Global Discovery Chemistry, Novartis Institute for Biomedical Research, 22 Windsor Street, Cambridge, Massachusetts 02139, United States.

Chemical Biology and Therapeutics, Novartis Institute for Biomedical Research, 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.

出版信息

ACS Med Chem Lett. 2019 Oct 10;10(11):1524-1529. doi: 10.1021/acsmedchemlett.9b00325. eCollection 2019 Nov 14.

Abstract

Small molecules that inhibit the metabolic enzyme NAMPT have emerged as potential therapeutics in oncology. As part of our effort in this area, we took a scaffold morphing approach and identified 3-pyridyl azetidine ureas as a potent NAMPT inhibiting motif. We explored the SAR of this series, including 5 and 6 amino pyridines, using a convergent synthetic strategy. This lead optimization campaign yielded multiple compounds with excellent in vitro potency and good ADME properties that culminated in compound .

摘要

抑制代谢酶烟酰胺磷酸核糖转移酶(NAMPT)的小分子已成为肿瘤学领域的潜在治疗药物。作为我们在该领域工作的一部分,我们采用了骨架变形方法,并确定3-吡啶基氮杂环丁烷脲为有效的NAMPT抑制基序。我们使用汇聚合成策略探索了该系列的构效关系,包括5-氨基吡啶和6-氨基吡啶。这次先导化合物优化研究产生了多种具有优异体外活性和良好药代动力学性质的化合物,最终得到了化合物。

相似文献

1
Scaffold Morphing Identifies 3-Pyridyl Azetidine Ureas as Inhibitors of Nicotinamide Phosphoribosyltransferase (NAMPT).
ACS Med Chem Lett. 2019 Oct 10;10(11):1524-1529. doi: 10.1021/acsmedchemlett.9b00325. eCollection 2019 Nov 14.
2
Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors.
J Med Chem. 2013 Jun 27;56(12):4921-37. doi: 10.1021/jm400186h. Epub 2013 Jun 13.
3
Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.
J Med Chem. 2016 Sep 22;59(18):8345-68. doi: 10.1021/acs.jmedchem.6b00697. Epub 2016 Aug 30.
4
Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
Bioorg Med Chem Lett. 2013 Sep 1;23(17):4875-85. doi: 10.1016/j.bmcl.2013.06.090. Epub 2013 Jul 6.
5
Structure based design of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors from a phenotypic screen.
Bioorg Med Chem Lett. 2018 Feb 1;28(3):365-370. doi: 10.1016/j.bmcl.2017.12.037. Epub 2017 Dec 18.
7
SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).
Bioorg Med Chem Lett. 2017 Aug 1;27(15):3317-3325. doi: 10.1016/j.bmcl.2017.06.018. Epub 2017 Jun 14.
9
Discovery of potent and efficacious cyanoguanidine-containing nicotinamide phosphoribosyltransferase (Nampt) inhibitors.
Bioorg Med Chem Lett. 2014 Jan 1;24(1):337-43. doi: 10.1016/j.bmcl.2013.11.006. Epub 2013 Nov 14.
10
Identification of novel Nicotinamide Phosphoribosyltransferase (NAMPT) inhibitors using computational approaches.
J Biomol Struct Dyn. 2018 Apr;36(5):1306-1328. doi: 10.1080/07391102.2017.1322004. Epub 2017 May 17.

引用本文的文献

1
Channeling Nicotinamide Phosphoribosyltransferase (NAMPT) to Address Life and Death.
J Med Chem. 2024 Apr 25;67(8):5999-6026. doi: 10.1021/acs.jmedchem.3c02112. Epub 2024 Apr 5.
2
Synthesis, and biological evaluation of EGFR/HER2-NAMPT conjugates for tumor treatment.
Mol Divers. 2024 Aug;28(4):2617-2636. doi: 10.1007/s11030-023-10701-y. Epub 2023 Jul 23.
3
Nicotinamide Adenine Dinucleotide (NAD) Metabolism as a Relevant Target in Cancer.
Cells. 2022 Aug 24;11(17):2627. doi: 10.3390/cells11172627.
4
From Rate-Limiting Enzyme to Therapeutic Target: The Promise of NAMPT in Neurodegenerative Diseases.
Front Pharmacol. 2022 Jul 12;13:920113. doi: 10.3389/fphar.2022.920113. eCollection 2022.
5
Put a ring on it: application of small aliphatic rings in medicinal chemistry.
RSC Med Chem. 2021 Jan 7;12(4):448-471. doi: 10.1039/d0md00370k. eCollection 2021 Apr 28.

本文引用的文献

1
Nicotinamide Phosphoribosyltransferase Inhibitor as a Novel Payload for Antibody-Drug Conjugates.
ACS Med Chem Lett. 2018 Jun 28;9(8):838-842. doi: 10.1021/acsmedchemlett.8b00254. eCollection 2018 Aug 9.
2
Structure based design of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors from a phenotypic screen.
Bioorg Med Chem Lett. 2018 Feb 1;28(3):365-370. doi: 10.1016/j.bmcl.2017.12.037. Epub 2017 Dec 18.
3
Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co-treatment with nicotinic acid.
Toxicol Mech Methods. 2015 Mar;25(3):201-11. doi: 10.3109/15376516.2015.1014080. Epub 2015 Apr 20.
4
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer.
Pharmacol Ther. 2015 Jul;151:16-31. doi: 10.1016/j.pharmthera.2015.02.004. Epub 2015 Feb 21.
5
Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase.
Toxicol Sci. 2015 Mar;144(1):163-72. doi: 10.1093/toxsci/kfu268. Epub 2014 Dec 11.
7
NAD as a genotype-specific drug target.
Chem Biol. 2013 Nov 21;20(11):1307-8. doi: 10.1016/j.chembiol.2013.11.001.
8
Medicinal chemistry of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors.
J Med Chem. 2013 Aug 22;56(16):6279-96. doi: 10.1021/jm4001049. Epub 2013 May 31.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验